Artemis client, US Foods, honed in on their data to support the need for a new dermatological point solution that could dramatically cut costs and increase ease of access to treatment for workers with an increasingly common skin condition. Read on to see:
US Foods is one of America’s great food companies and a leading foodservice distributor, partnering with approximately 300,000 restaurants and foodservice operators to help their businesses succeed. With over 28,000 employees and more than 160 locations, US Foods provides its customers with a broad and innovative food offering and a comprehensive suite of e-commerce, technology, and business solutions.
Benefits leaders use data to pinpoint opportunities, back the need for pilot studies and help their dollars go further in caring for their workforce. Artemis client, US Foods®, honed in on their data to justify the need for a new dermatological point solution to potentially cut costs while increasing easy treatment access for workers with a skin condition that impacts more than 8 million Americans.
US Foods® uses the Artemis platform to steer decisions and support the implementation of pioneering pilots within the company’s benefits ecosystem.
One opportunity observed through Artemis analytics was brought to the forefront through reviewing total Rx specialty spend, which continues to increase each year.
Narrowing in on specialty prescription spending through Artemis reporting showed that roughly a third of specialty costs were attributed to medications commonly used to treat psoriasis. Psoriasis is a multisystemic disease in which skin cells accumulate, forming dry, itchy patches. This condition has many common comorbidities, including psoriatic arthritis, excess weight, metabolic syndrome, cardiovascular disease, inflammatory bowel disease, and depression.
By measuring the impact of psoriasis within their employee population with Artemis, US Foods found that although less than 1% of their population struggles with psoriasis, the cost for treating this disease is extremely high and is expected to increase.
One way that US Foods is thinking outside the box to curb costs in this fragment of their population is through a pilot study with a new phototherapy point solution, Zerigo, for chronic skin condition management. The FDA-cleared, convenient at-home treatment has an 81% patient “good, great, or life-changing” satisfaction rating.
If the pilot is a success, it will provide an opportunity for a one-time ticket price point compared to ongoing drug consumption, which ultimately could provide an alternative to costly biologics, slashing specialty spending for this small employee segment. US Foods will then be able to reinvest millions of dollars into other programs that impact their larger population while still catering to the needs of their small fraction of workers with this multisystemic disease.
Artemis Health is helping our customers take action with their benefits data, and that’s just the beginning of what we can do.